SITUATION

U.S. manufacturer was launching their first product, an oral oncolytic for a rare sub-indication.

​

Forecast in the U.S. was ~ 500 patients.

​

Challenged to increase revenue potential for the brand.

APPROACH

Archbow consultant recognized the opportunity for a Named Patient Program (NPP) in EU & ROW markets.

​

Identified & vetted a vendor with EU & ROW capabilities.

​

Established protocol to import product, sell in ex-U.S. markets, collect & report AEs consistently, and communicate with HCPs.

RESULTS

By end of year 1, 1/3 of all product sales occurring outside of U.S.

​

Distribution eventually expanded to multiple markets, including EU, Asia, & South America.

​

All NPP sales counted toward U.S. revenue (top line).

​

Leveraged market & HCP knowledge to ensure smooth transitions to commercial operations as product was  approved in ex-U.S. markets.